Instruction for use: EnablexI want this, give me price
Active substance: Darifenacin
Antispasmodics [Spazmolitiki myotropic]
The nosological classification (ICD-10)
F98.0 Enuresis inorganic nature
Urinary incontinence., Urinary incontinence etiology nonhormonal, Urinary incontinence inorganic etiology, Functional enuresis in children, Children's enuresis
N31.1 Reflex neuropathic bladder, not elsewhere classified
hyperreflexia, Overactive Bladder, detrusor hyperreflexia, detrusor hyperreflexia
N39.3 Involuntary urination
Urinary incontinence in women, Anishuriya, Urinary incontinence
N39.4 Other specified types of urinary incontinence
Urinary incontinence, Bed-wetting, Frequent nocturnal urination, Urinary incontinence in women, Anishuriya, Primary nocturnal enuresis, Primary nocturnal enuresis in children
R32 Urinary incontinence unspecified
daytime enuresis, Idiopathic bladder instability, Urinary incontinence, nocturia, The disorder of the bladder sphincter function, Spontaneous urination, Mixed forms of urinary incontinence, Functional disorders of micturition, Functional micturition disorders, Functional enuresis in children, Enuresis
R39.1 Other difficulties with micturition
Frequent urination, urinary retention, strangury, Obstructed flow of urine, Violation of urination, Violation of urination, Violation of bladder emptying, Violation of the outflow of urine, Frequent urination, Abnormalities of urination
Sustained-release tablets, film-coated Table 1.
darifenacin hydrobromide 8.929 mg
(Corresponds to 7.5 mg darifenacin or 15 bases)
excipients: calcium dihydrogen phosphate; Valium; magnesium stearate
coated tablets: hypromellose 2910; polyethylene glycol 4000; talc; titanium dioxide (E171); for tablets, sustained-release, film-coated, 15 mg (optional) - Iron oxide yellow (E172); iron oxide red (E172)
in blister 7 or 14 pcs .; In the paper cartons 1, 2 (7 pcs.) or 1, 2, 4, 7 (14 pcs.) blisters.
Dosing and Administration
Inside, swallowed whole, without chewing, not sharing or crush.
The drug should be one time per day, with some liquid, regardless of the meal.
For adult patients, the recommended initial dose - 7.5 mg / day.
With insufficient therapeutic effect of the dose can be increased to 15 mg / day. Dose escalation should be performed 2 weeks after initiation of therapy based on the patient's individual response to treatment.
Elderly patients. Elderly patients correction dose is not required.
Use in impaired renal function. In patients with impaired renal function dose adjustment is required.
Application for violations of liver function. In patients with moderate liver function impairment (class B on a scale Child-Pough) should not exceed a daily dose of 7.5 mg Enableks.
Conditions of supply of pharmacies
In the dark place at a temperature no higher than 30 ° C.
Keep out of the reach of children.
Do not use beyond the expiration date printed on the package.